As ASCs become more popular and cases continue migrating to outpatient settings, leaders need to learn how to scale appropriately, according to Earl Kilbride, M ...
IMVARIA has gained 510 (k) clearance from the US Food and Drug Administration (FDA) for its AI-powered healthcare tool, ...
NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/98.FiJKC4GV.js ...
Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated decrease of approximately 25% over ...
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
AngioDynamics Inc (ANGO) reports a robust 9% revenue growth, driven by MedTech and mechanical thrombectomy segments, while ...
Price discrepancies for the same medical procedures show how unfair insurance practices erode trust, leaving patients ...
A discussion with Campbell Rogers, MD, regarding advances in AI technology for prevention and management of coronary artery disease.
Q2 2025 Earnings Call Transcript January 8, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.04, ...
Michael Scheuer, of Winter Garden, pleaded guilty to one count of computer fraud and one count of aggravated identity theft as part of a plea deal with prosecutors.
Outpatient spine procedures have seen explosive growth over the last 10 years — a pattern that could continue as technology rapidly advances in the industry.